Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Esser

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Antimicrobial Resistance and Infection Control|July 24, 2021
Evaluation of GeneXpert PA assay compared to genomic and (semi-)quantitative culture methods for direct detection of Pseudomonas aeruginosa in endotracheal aspiratesThomas Ewout van der Schalk, Jasmine Coppens, Leen Timbermont, et al.
The New England Journal of Medicine|May 15, 2007
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesSuzanne M Garland, Mauricio Hernandez-Avila, Cosette M Wheeler, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Lancet. Respiratory Medicine|June 10, 2022
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trialHugh Montgomery, F D Richard Hobbs, Francisco Padilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019Myron J Levin, Andrew Ustianowski, Steven Thomas, et al.
Npj Antimicrobials and Resistance|May 8, 2026
Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patientsThomas E van der Schalk, Matilda Berkell, An Hottebeekx, et al.
Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.
Vaccine|May 15, 2007
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineSven-Eric Olsson, Luisa L Villa, Ronaldo L R Costa, et al.
Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
The New England Journal of Medicine|April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Antimicrobial Resistance and Infection Control|July 24, 2021
Evaluation of GeneXpert PA assay compared to genomic and (semi-)quantitative culture methods for direct detection of Pseudomonas aeruginosa in endotracheal aspiratesThomas Ewout van der Schalk, Jasmine Coppens, Leen Timbermont, et al.
The New England Journal of Medicine|May 15, 2007
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesSuzanne M Garland, Mauricio Hernandez-Avila, Cosette M Wheeler, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Lancet. Respiratory Medicine|June 10, 2022
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trialHugh Montgomery, F D Richard Hobbs, Francisco Padilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019Myron J Levin, Andrew Ustianowski, Steven Thomas, et al.
Npj Antimicrobials and Resistance|May 8, 2026
Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patientsThomas E van der Schalk, Matilda Berkell, An Hottebeekx, et al.
Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.
Vaccine|May 15, 2007
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineSven-Eric Olsson, Luisa L Villa, Ronaldo L R Costa, et al.
Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
The New England Journal of Medicine|April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
Pageof 10